Advertisement

Investigational New Drugs

, Volume 19, Issue 4, pp 329–333 | Cite as

A Phase II Trial of 9-Aminocaptothecin (9-AC) as a 120-h Infusion in Patients with Non-Small Cell Lung Cancer

  • Everett E. Vokes
  • Gary S. Gordon
  • Charles M. Rudin
  • Ann M. Mauer
  • Sylvia Watson
  • Stuart Krauss
  • Rose Arrieta
  • Harvey M. Golomb
  • Philip C. Hoffman
Article

Abstract

In a previous phase II trial of thesynthetic topoisomerase I inhibitor,9-aminocamptothecin (9-AC), given as a72-h infusion, we identified modestsingle agent activity of 9% in patientswith previously untreated advancednon-small cell lung cancer (NSCLC).Preclinical studies suggested that a moreprolonged continuous infusion of the drugmight lead to greater antitumor activity. Aphase I study recommended a phase II doseof 25 μg/m2/hr for 120 h(3000 μg/m2 over 5 days),administered for 2 consecutive weeks of a3-week cycle. We utilized this schedule andenrolled 13 chemotherapy-naıve patientswith Stage IIIB and IV NSCLC in this trial:median age 67 (range 57–74); 46% male;92% stage IV; and median performancestatus 1. Twelve patients are availablefor response and toxicity evaluation after2 cycles of therapy. One patient achieveda partial response. Four patients hadstable disease while seven patients hadprogressive disease. Patients with stableor progressive disease after two cyclesreceived no additional 9-AC, and wereoffered conventional chemotherapy. Themedian survival time was 10.2 months andthe one-year survival rate 28% (95%confidence interval, 5–58%). Significant toxicities includedmyelosuppression, fatigue, and anorexia. One patient had grade 4 neutropeniafollowing the first week of cycle 2, anddid not receive additional therapy. Therewere no neutropenia-related infections.These data suggest that this prolongedschedule is unlikely to increase 9-AC'svery modest activity in NSCLC above thatseen with the simpler 72-hadministration schedule. Furtherevaluation of 9-AC in NSCLC is notrecommended.

9-aminocamptothecin non-small cell lung cancer 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

REFERENCES

  1. 1.
    Ginsberg R, Vokes EE, Raben A: Non-small cell lung cancer. In: DeVita Jr VT, Hellman S, Rosenberg SA (Eds), Cancer – Principles and Practice of Oncology.6th Edition,J.B. Lippincott Co., Philadelphia, (in press).Google Scholar
  2. 2.
    Hoffman PC, Mauer AM, Vokes EE: Lung Cancer Lancet355: 479–485,2000Google Scholar
  3. 3.
    Pantazis P, Giovanella BC, Rothenberg ML (Eds): The Camptothecins: From Discovery to the Patient.New York Academy of Sciences, New York, NY803:1–328, 1996Google Scholar
  4. 4.
    Takomoto CH, Arbuck SG:The camptothecins. In: Chabner BA, Longo DL (Eds),Cancer Chemotherapy and Biotherapy: Principles and Practice2nd Edition.Philadelphia, PA. Lippincott-Raven,463–484,1996Google Scholar
  5. 5.
    Rothenberg ML: Topoisomerase I inhibitors: Review and update. Ann Oncol 8837–8855,1997Google Scholar
  6. 6.
    Rothenberg ML, Kuhn JG, Burris HA, Nelson J, Eckardt JR, Tristan-Morales M, Hilsenbeck SG, Weiss GR, Smith LS, Rodriguez GI:Phase I and pharmacokinetic trial of weekly CPT-11.J Clin Oncol11:2194–2204,1993Google Scholar
  7. 7.
    De Forni M, Bugat R, Chabot GG, Culine S, Extra M, Gouyette A, Madeline I, Marty M, Mathieu-Boue A: Phase I and pharmacokinetics study of the camptothecins derivative irinotecan, administered on a weekly schedule in cancer patients. Cancer Res54:4347–4354, 1994Google Scholar
  8. 8.
    Fukuoka M, Niitani H, Suzuki A, Motomiya M, Hasegawa K, Nishiwaki Y, Kuriyama T, Ariyoshi Y, Negoro S, Masuda N: A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol10: 16–20,1992Google Scholar
  9. 9.
    Masuda N, Fukuoka M, Kudoh S, Kusunoki Y, Matsui K, Nakagawa K, Hirashima T, Tamanoi M, Nitta T, Yana T: Phase I study of irinotecan and cisplatin with granulocyte colonystimulating factor support for advanced non-small-cell lung cancer.J Clin Oncol12:90–96,1994Google Scholar
  10. 10.
    Rowinsky EK, Grochow LB, Sartorius SE, Bowling MK, Kaufmann SH, Peereboom D, Donehower RC: Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors.J Clin Oncol14:1224–1235, 1996Google Scholar
  11. 11.
    Vokes EE, Janisch L, Spector B, Lestingi T, Gupta E, Schilsky RL, Ratain MJ: A phase I dose-intensification study of irinotecan (CPT-11) with maximized supportive care.Cancer Ther 1(4):223–228,1998Google Scholar
  12. 12.
    DeVore RF, Johnson DH, Crawford J, Garst J, Dimery IW, Eckardt J, Eckhardt SG, Elfring GL, Schaaf LJ, Hanover CK, Miller LL:Phase II study of irinotecan plus cisplatin in patients with advanced non-small cell lung cancer.J Clin Oncol 17(9):2710–2720,1999Google Scholar
  13. 13.
    Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura t, Yokoyama A, Fukuoka M, Mori K, Watanabe K, Tamura T, Saijo N, Yoshimura K: Randomized phase III study of irinotecan (CPT-11) and cisplatin versus etoposide and cisplatin in extensive-disease small-cell lung cancer: Japan Clinical Oncology Group Study (JCOG9511).Proc Am Soc Clin Oncol 19: 483a (Abstr. 1887), 2000Google Scholar
  14. 14.
    Oshita F, Noda K, Nishiwaki Y, Fujita A, Kurita Y, Nakabayashi T, Tobise K, Abe S, Suzuki S, Hayashi I, Kawakami Y, Matsuda T, Tsuchiya S, Takahashi S, Tamura T, Saijo N: Phase II study of irinotecan and etoposide in patients with metastatic non-small cell lung cancer.J Clin Oncol15(1): 304–309,1997Google Scholar
  15. 15.
    Perez-Soler R, Fossella FV, Glisson BS, Lee JS, Murphy WK, Shin DM, Kemp BL, Lee JJ, Kane J, Robinson RA, Lippman SM, Kurie JM, Huber MH, Raber MN, Hong WK: Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy.J Clin Oncol14:503–513,1996Google Scholar
  16. 16.
    Lynch Jr TJ, Kalish L, Strauss G, Elias A, Skarin A, Shulman LN, Posner M, Frei 3rd E:Phase II study of topotecan in metastatic non-small-cell lung cancer.J Clin Oncol12:347–352, 1994Google Scholar
  17. 17.
    Ardizzoni A, Hansen H, Dombernowsky P, Gamucci T, Kaplan S, Postmus P, Giaccone G, Schaefer B, Wanders J, Verweij J: Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: A phase II study in patients with refractory and sensitive disease.J Clin Oncol 15(5): 2090–2096, 1997Google Scholar
  18. 18.
    Dahut W, Harold N, Takimoto C, Allegra C, Chen A, Hamilton JM, Arbuck S, Sorensen M, Grollman F, Nakashima H, Lieberman R, Liang M, Corse W, Grem J: Phase I and pharmacologic study of 9-aminocamptothecin given by 72-h infusion in adult cancer patients.J Clin Oncol14:1236–1244,1996Google Scholar
  19. 19.
    Rubin E, Wood V, Bharti A, Trites D, Lynch C, Hurwitz S, Bartel S, Levy S, Rosowsky A, Toppmeyer D, Kufe D: A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin.Clin Canc Res1:269–276,1995Google Scholar
  20. 20.
    Takimoto CH, Dahut W, Marino MT, Nakashima H, Liang MD, Harold N, Lieberman R, Arbuck SG, Band RA, Chen AP, Hamilton JM, Cantilena LR, Allegra CJ, Grem JL: Pharmacodynamics and pharmacokinetics of a 72-h infusion of 9-aminocamptothecin in adult cancer patients.J Clin Oncol 15(4):1492–1501,1997Google Scholar
  21. 21.
    Vokes EE, Ansari RH, Masters GA, Hoffman PC, Klepsch A, Ratain MJ, Sciortino DF, Lad TE, Krauss S, Fishkin PAS, Golomb HM: A phase II study of 9-aminocamptothecin in advanced non-small-cell lung cancer.Ann Oncol9:1085–1090, 1998Google Scholar
  22. 22.
    Minami H, Lad TE, Nicholas MK, Vokes EE, Ratain MJ:Pharmacokinetics and pharmacodynamics of 9-aminocamptothecin infused over 72 h in phase II studies.Clin Canc Res5:1325–1330,1999Google Scholar
  23. 23.
    Saltz LB, Kemeny NE, Tong W, Harrison J, Berkery R, Kelsen DP:9-aminocamptothecin by 72-h continuous intravenous infusion is inactive in the treatment of patients with 5-fluorouracil-refractory colorectal carcinoma.Cancer8(9): 1727–1732,1997Google Scholar
  24. 24.
    Pazdur R, Medgyesy DC, Winn RJ, Dakhil SR, Moore DF, Scalzo A, Hoff PM, Arbuck SG, Abbruzzese JL: Phase II trial of 9-aminocamptothecin (NSC 603071) administered as a 120-h continuous infusion weekly for three weeks in metastatic colorectal carcinoma.Invest New Drugs16:341–346, 1999Google Scholar
  25. 25.
    Pazdur R, Diaz-Canton E, Ballard WP, Bradof JE, Graham S, Arbuck SG, Abbruzzese JL, Winn R: Phase II trial of 9-aminocamptothecin administered as a 72-h continuous infusion in metastatic colorectal carcinoma.J Clin Oncol15: 2905–2909,1997Google Scholar
  26. 26.
    Siu LL, Oza AM, Eisenhauer EA, Firby PS, Thiessen JJ, Michael M, Wainman N, Manzo J, Feld R, Goldberg RA, Moore MJ: Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation given as a 24-h continuous infusion weekly times four every 5 weeks.J Clin Oncol16(3): 1122–1130,1998Google Scholar
  27. 27.
    Lad T, Rosen F, Sciortino D, Brockstein B, Keubler JP, Arrieta R, Vokes E. Phase II trial of aminocamptothecan (9-AC/DMA) in patients with advanced squamous cell head and neck cancer. Invest New Drugs (in press)Google Scholar
  28. 28.
    Kraut EH, Balcerzak SP, Young D, O'Rourke MA, Petrus JJ, Kuebler JP, Mayernik DG: A phase II study of 9-aminocamptothecin in patients with refractory breast cancer. Cancer Invest 18(1):28–31,2000Google Scholar
  29. 29.
    Israel VP, Gandara D, Perez E, Dimery I, Synold T, Longmate J, Doroshow JH: 9-Aminocamptothecin (9AC) (NSC 603071) + GCSF in extensive small cell lung cancer (ESCLC): A phase II California cancer consortium trial.Proc Am Soc Clin Oncol 19:528a (2073), 2000Google Scholar
  30. 30.
    Houghton PJ, Cheshire PJ, Hallman JD 2nd, Lutz L, Friedman HS, Danks MK, Houghton JA:Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors.Cancer Chemother Pharmacol 36(5):393–403, 1995Google Scholar
  31. 31.
    Stadler WM, Vogelzang NJ, Hoffman PC, Arrieta R, Masters G, Fishkin P, Gibbons J, Lad TE, Vokes EE: CI-980 in renal cell and non-small cell lung cancer: multi-institutional trials from the University of Chicago Phase II Consortium.Cancer Therapeutics1:318–320, 1998Google Scholar

Copyright information

© Kluwer Academic Publishers 2001

Authors and Affiliations

  • Everett E. Vokes
    • 1
  • Gary S. Gordon
    • 1
  • Charles M. Rudin
    • 1
  • Ann M. Mauer
    • 1
  • Sylvia Watson
    • 1
  • Stuart Krauss
    • 1
  • Rose Arrieta
    • 1
  • Harvey M. Golomb
    • 1
  • Philip C. Hoffman
    • 1
  1. 1.Section of Hematology/Oncology, Department of Medicine and Cancer Research CenterUniversity of ChicagoChicagoU.S.A.

Personalised recommendations